


# **Biotech 85**

## **USA**



## **The World Biotech Report 1985**

### **Volume 2: USA**

**Proceedings of Biotech '85 USA,  
Washington DC, October 1985**

# **Biotech 85**

**The World Biotech Report 1985**  
**Volume 2: USA**

**Proceedings of Biotech '85 USA,  
Washington DC, October 1985**

*onTime*

**London : New York : Singapore**



The World biotech report 1985.

Vol. 2, USA : the proceedings of Biotech '85

USA Washington, D.C. October 1985.

1. Biotechnology

I. Biotech '85 USA Conference : 1985 : Washington,  
D.C.

660'.6      TP248.2

ISBN 0-86353-125-7

© Online International Inc 1985  
Printed in the USA

The papers in this book are presented by the individual authors.  
Online, therefore, accepts no liability for any errors or omissions.

No part of this book may be reproduced, stored in any form, by any  
means, electronic, mechanical, photocopying, microfilming, recording  
or otherwise, without written permission from the publisher.

**Online Publications**

A division of Online International Ltd: London, New York, Singapore

## Introduction

The time has come for biotechnology to get to work. Exotic promises of plants that can grow porkchops, pizza flavored popcorn and bacteria that can perform alchemy, turning lead into gold, no longer seem appropriate. We have learned a lot in the past five years and expectations now about the future of the new industry are much more realistic - and still promising amazing new developments. Our experiences now can help us to make true and valuable predictions about the future products we can expect from the new science.

In addition to the increased sophistication that comes from the laboratory we have learned much about the business of biology. Some of the promised products are now about to come into the marketplace. There are new varieties of plants, new proteins added to the pharmacopea, and new ways of designing the future products with the aid of computers. We have new methods for producing the products after they have been proven in the laboratory. We have had experience with how these new products can be marketed and we have encountered regulatory, patenting and licensing issues that were not always anticipated. Imaginative new approaches to funding research and development projects have been found. There is a lot to talk about when we all compare notes taken over the past year.

The breadth of papers presented in this volume, written by those in the trenches, will apprise us of advances, alert us to pitfalls and educate us about that which is to come.




Biotech 85 USA is organized and controlled by Online International Inc. The conference and exhibition continue the highly successful series of events which started with Biotech '83 in London.

Online is one of the world's leading specialists in the design, coordination and management of conferences and exhibitions concerned with business applications of leading edge technology. Operating for 14 years, Online's staff numbers more than 120 technology consultants and event specialists, based in London, New York and Singapore.

Online International Inc.  
989 Avenue of the Americas, New York, NY 10018  
Phone: (212) 279-8890 Fax: (212) 279-8898

## Industry & Program Advisory Committees




Ron Ellis  
Research Fellow  
Merck, Sharp &  
Dohme



Pat Gage  
Vice President  
Research & Development  
Hoffmann-LaRoche



Catherine Propst  
Vice President  
Research & Development  
Flow General



Garfield Royer  
Director,  
Biotechnology Div  
Corporate Research  
Amoco Corporation



Thelma Carter  
Partner  
Biotechnology Review  
Associates



Anthony Dennis  
Manager, Cellular &  
Molecular Biotechnology  
Section  
Battelle Laboratories



James Dwyer  
Senior Vice President  
Millipore



Douglas Eveleigh  
Professor of  
Microbiology  
Rutgers University



Alison Tauton-Rigby  
Vice President &  
General Manager  
Vivotech

# Authors

Allen B	Battelle Columbus Labs	USA	447
Anderson D	Cyanotech Corp	USA	85
Andresen O	Novo Industri, AS	Denmark	253
Arnold EC	UOP, Inc.	USA	213
Birch JR	Celltech Ltd	UK	179
Bjurstrom E	Fluor Engineers/Daniel Engineering & Construction	USA	429
Bott R	Genentech, Inc.	USA	51
Boraston R	Celltech Ltd	UK	179
Boss M	Celltech Ltd	UK	179
Brill W	Agracetus	USA	7
Chait E	du Pont	USA	123
Chaleff RS	du Pont	USA	97
Chui CF	du Pont	USA	97
Clay D	EPA	USA	121
Coleman DR	Southern Research Institute	USA	241
Cysewski G	Cyanotech Corp	USA	85
Delente J	Chembiotech	USA	367
Donlon J	FDA	USA	499
Dunne CP	US Army Natick R&D Center	USA	561
Ellis R	Merck, Sharp & Dohme Research Labs	USA	511
Evans D	DNA Plant Technology Corp	USA	61
Evans R	Twyford Plant Labs, Inc.	USA	77
Falco SC	du Pont	USA	97
Feder J	Monsanto Company	USA	169
Ferrell TM	Southern Research Institute	USA	241
Fiksel J	Arthur D. Little, Inc.	USA	1

Frazer FR	Southern Research Institute	USA	241
Fries L	Merck & Co., Inc.	USA	393
Gage P	Hoffmann-LaRoche	USA	305
Garner C	Hybritech	USA	501
Goldstein J	Saidman, Stern, Kessler & Goldstein	USA	9
Haigh G	Cyanotech Corporation	USA	85
Hansen L	USDA	USA	539
Hofer M	Johnson & Johnson Corp	USA	17
Huxsoll D	US Army Medical Research Institute of Infect. Dis.	USA	477
Jarvis A	Damon Biotech, Inc.	USA	503
Jaworski EG	Monsanto Company	USA	31
Jost J	Genentech, Inc.	USA	429
Kalter RJ	Cornell University	USA	529
Kapper F	Pentagon	USA	333
Karny G	Finnegan, Henderson, Farabow, Garrett & Dunner	USA	141
Karuna-Karan A	Cyanotech Corporation	USA	85
Kelly P	Monsanto Corp	USA	31
Keesom WH	UOP, Inc.	USA	213
Klausner A	Bio/Technology	USA	265
Kumosinski T	USDA Eastern Res. Center	USA	549
Lambert K	Celltech Ltd	UK	179
Laughlin T	Southern Research Institute	USA	241
Lee V	NovoVentures, Inc.	USA	275
Lesser W	Cornell University	USA	529
Low D	Pharmacia Fine Chemicals	Sweden	467
Luli GW	Battelle Columbus Labs	USA	447
Marron MT	Office of Naval Research	USA	483
Mazur B	du Pont	USA	97
Mauvais CJ	du Pont	USA	97
McSweeney P	W R Grace & Co.	USA	349
Milligan R	Cornell University	USA	529
Mueller WH	UOP, Inc.	USA	213



Nayyar DK	USDA	USA	539
Neidleman S	Cetus Corporation	USA	189
Newburgh RW	Office of Naval Research	USA	483
Nichols K	Alza Corp	USA	321
Nystrom LE	Pharmacia AB	Sweden	467
Perun T	Abbott Laboratories	USA	313
Pressen H	USDA, Eastern Regional Research Center	USA	549
Prestowitz CV	U.S. Department of Commerce	USA	585
Propst C	Flow General	USA	283
Riley R	Arthur D. Little, Inc.	USA	339
Rollo D	Humana, Inc.	USA	377
Rosenbaum, E	Arthur D. Little, Inc.	USA	359
Royer G	Amoco Corporation	USA	201
Sachais B	Ciba-Geigy Corporation	USA	291
Sayler G	University of Tennessee	USA	3
Schaeffer H	Burroughs Wellcome	USA	301
Schmell E	Office of Naval Research	USA	483
Schmergel G	Genetics Institute	USA	337
Schoemaker H	Centocor, Inc.	USA	495
Seay N	Isaksen, Lathrop, Esch, Hart & Clark	USA	39
Shuler M	Cornell University	USA	231
Stern Stephen	William Harvey Life Products	USA	131
Swartz JR	Genentech, Inc.	USA	429
Talbot B	National Institute of Allergy & Infect. Diseases	USA	117
Taylor R	Arthur D. Little, Inc.	USA	381
Tauton-Rigby A	Vivotech	USA	517
Thompson PW	Celltech Ltd	UK	179
Tibbetts R	National Science Foundation	USA	577
Tolbert W	Monsanto	USA	169

Urquhart J	Alza Corp	USA	321
Volesky B	McGill University	USA	409
Walker K	Plant Genetics, Inc.	USA	109
Walsh W	US Department of State	USA	119

# Contents

## Issues concerning environmental release

Issues concerning environmental releases of genetically - modified organisms	Joseph Fiksel Arthur D. Little, Inc.	1
Consequences of environmental release of genetically engineered microorganisms	Gary Sayler University of Tennessee	3
Release of genetically engineered organisms to improve agriculture	Winston Brill Agracetus Corporation	7

## Patent issues—new outlooks

Legal and administrative developments in depository practice - US & abroad	Jorge Goldstein Saidman, Stern, Kessler & Goldstein	9
US biotechnology deposit considerations - a corporate view	Mark Hofer Johnson & Johnson	17
✓ Transfer of biological materials from universities to corporations	Patrick Kelly Monsanto	31
Proprietary protection of plants and varieties in the U.S.	Nicholas Seay Isaksen, Lathrop, Esch, Hart & Clark	39

## **Protein design & function—1**

Modeling & crystallographic analysis of site-specific mutants of subtilisin	Richard Bott Genentech, Inc.	51
---	---------------------------------	----

## **Crops for consumers**

Crop improvements using tissue culture	David Evans DNA Plant Technology Corp	61
Tissue culture - a tool for plant improvement	Ralph Evans Twyford Plant Laboratories	77
Commercial applications of large-scale culture of micro-algae	Arthur Karuna-Karan Cyanotech Corp	85

## **Crops for farmers**

Cloning herbicide resistance genes into and out of plants	Barbara Mazur du Pont	97
Commercialization of agricultural biotechnology	Keith Walker Plant Genetics, Inc.	109

## **Federal coordination of regulation**

The role of the National Institutes of Health	Bernard Talbot NIH	117
International implications of the regulation of biotechnology	William Walsh Department of State	119
Federal coordination of regulation	Don Clay Environmental Protection Agency	121

## Technology transfer

Funding high risk research through federal R&D	Roland Tibbetts National Science Foundation	577
Licensing & technology transfer in the biotechnology industry	Edward Chait du Pont	123
Opportunities created by state & government initiatives to foster technology transfer	Stephen Stern William Harvey Life Products	131
Biotechnology Licensing	Geoffrey Karyn Finnegan, Henderson, Farabow, Garrett & Dunner	141

## Mammalian cells—producers of pharmaceuticals

Perfusion systems for plant scale mammalian cell culture production	William Tolbert Monsanto	169
Large scale production of monoclonal antibodies	Michael Boss Celltech	179

## Enzymes in a manufacturing environment

Nontraditional biocatalysis	Saul Neidleman Cetus Corp	189
Biocatalysis in industry: problems and opportunities	Garfield Royer Amoco Corp	201

## **Immobilized systems**

A versatile, incompressible, high binding capacity protein immobilization system for lab & industrial scale use	Bill Keesom UOP, Inc.	213
Immobilized whole cell bioreactors: potential tools for directing cellular metabolism	Michael Shuler Cornell University	231

## **Biotechnology & the consumer**

Biotechnology in the cosmetics industry	Thomas Laughlin Southern Research Institute	241
Obstacles to new enzyme applications	Otto Andresen Novo Industri AS	253
The media: biotech's most pervasive consumer product so far	Arthur Klausner Bio/Technology	265
Biotech at the checkout counter: the underplayed potential	Vivian Lee NovoVentures, Inc.	275

## **Developing new drugs—1**

Modern technologies for the discovery of new pharmaceuticals	Catherine Propst Flow General	283
Discovering & clinically evaluating drugs for the treatment of senile dementia	Barry Sachais Ciba-Geigy Corp	291
Recent advances in antiviral chemotherapy: substrates of viral thymidine kinase	Howard Schaeffer Burroughs Wellcome	301

## Developing new drugs—2

Pharmaceutical design by modification of natural bioactive agents	Pat Gage Hoffmann-LaRoche	305
The use of molecular modeling and computer graphic techniques in the design of new cardiovascular drugs	Thomas Perun Abbott Labs	313
Delivery systems & pharmacodynamics in new drug research & development	John Urquhart Alza Corp	321

## Biotechnology: international trade

DOD and biotechnology	Francis Kapper Pentagon	333
Technology transfer: industry perspectives	Gabriel Schmergel Genetics Institute	337
Japanese biotech industry development	Clyde Prestowitz US Department of Commerce	585

## Strategic planning

Research and development planning for biotechnologies	Robert Riley Arthur D. Little, Inc.	339
Biotechnology investments ready for harvesting - unique opportunities for large companies	Paul McSweeney W R Grace & Co.	349
Evaluating market potentials for novel therapeutics - incorporating uncertainty	Eric Rosenbaum Arthur D. Little, Inc.	359
Trends in biotechnology: strategic options for new biotech firms	Jacques Delente Chembitech	367

## **Diagnosis related groups & the biotech market**

Diagnosis related groups & the biotech market	David Rollo Humana, Inc.	377
---	-----------------------------	-----

## **Purity & production of biotechnology products**

Application of high performance affinity chromatography to biotechnology	Richard Taylor Arthur D. Little, Inc.	381
Concentration of labile compounds by reverse osmosis	Louis Fries Merck & Co., Inc.	393

## **Strategies for bioprocessing**

Bioprocess modeling and optimization	Bohumil Volesky McGill University	409
Operational parameters and broth properties affecting oxygen transfer in bioreactors	Edward Bjurstrom Fluor Technology & Daniel Engineering	429
A gradient-feed process for obtaining high cell densities and control of product expression for recombinant <i>Escheria coli</i>	Billy Allen Battelle Columbus Labs	447
The impact of affinity chromatography on the recovery of biologicals for the pharmaceutical industry	Duncan Low Pharmacia, Sweden	467



## National defense strategies & biotech

Biotechnology: it's role in solving military medical problems	David Huxsoll US Army Medical Research Institute of Infectious Diseases	477
US Navy basic research program in non-medical biotechnology	Eli Schmell Office of Naval Research	483

## Diagnostics—how do we get results?

New developments in cancer diagnostics and therapy	Hubert Schoemaker Centocor, Inc.	495
A regulatory perspective	Jerome Donlon FDA	499
Technical marketing - a case study	Cam Garner Hybritech	501

## Biotechnology driven changes

Production of biologicals in tissue culture: manufacturing barriers to market entry	Allan Jarvis Damon Biotech	503
Applications of recombinant DNA technology to vaccine development	Ron Ellis Merck, Sharp & Dohme Research Laboratories	511
The encapsulation of pancreatic islets as an alternative to insulin therapy	Alison Tauton-Rigby Vivotech	517
The economic implications of Bovine Somatotropin	Robert Milligan Cornell University	529